Comparison of an automated Borrelia indirect chemiluminescent immunoassay (CLIA) with a VlsE/C6 ELISA and Immunoblot

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 26, Issue 7, 2007, Pages 517-519

  Riesbeck, K ^a   Hammas, B ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Borrelia burgdorferi; Chemiluminescence; ELISA; Immunoblot; Serology

Indexed keywords

BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; BB0323 PROTEIN; BBA36 PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; OUTER SURFACE PROTEIN C; PROTEIN; PROTEIN G; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOMATION; BACTERIAL GENETICS; BACTERIUM DETECTION; BACTERIUM ISOLATE; BORRELIA AFZELII; BORRELIA BURGDORFERI; BORRELIA GARINII; BORRELIA INFECTION; CHEMOLUMINESCENCE; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOMEGALOVIRUS; DIAGNOSTIC PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; FEMALE; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOASSAY; IMMUNOBLOTTING; INCIDENCE; LYME DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCREENING; VARICELLA ZOSTER VIRUS;

ADOLESCENT; ADULT; AGED; BORRELIA BURGDORFERI; CHEMILUMINESCENT MEASUREMENTS; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LYME DISEASE; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SEROLOGIC TESTS;

EID: 34347407153     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-007-0329-x     Document Type: Article

References (10)

1. Centers for Disease Control and Prevention (2004) Lyme Disease-United States 2001-2002. Morb Mortal Wkly Rep 53:365-369
2. Rosa PA, Tilly K, Stewart PE (2005) The burgeoning molecular genetics of the Lyme disease spirochaete. Nat Rev Microbiol 3:129-143
3. Padula SJ, Dias F, Sampieri A, Craven RB, Ryan RW (1994) Use of recombinant OspC from Borrelia burgdorferi for serodiagnosis of early Lyme disease. J Clin Microbiol 32:1733-1738
4. Sung SY, McDowell JV, Marconi RT (2001) Evidence for the contribution of point mutations to vlsE variation and for apparent constraints on the net accumulation of sequence changes in vlsE during infection with Lyme disease spirochetes. J Bacteriol 183:5855-5861
5. Lawrenz MB, Hardham JM, Owens RT et al (1999) Human antibody responses to VlsE antigenic variation protein of Borrelia burgdorferi. J Clin Microbiol 37:3997-4004
6. Philipp MT, Marques AR, Fawcett PT, Dally LG, Martin DS (2004) C6 test as an indicator of therapy outcome for patients with localized or disseminated Lyme borreliosis. J Clin Microbiol 41:4955-4960
7. Hauser U, Lehnert G, Wilske B (1999) Validity of interpretation criteria for standardized Western blots (immunoblots) for serodiagnosis of Lyme borreliosis based on sera collected throughout Europe. J Clin Microbiol 37:2241-2247
8. Aguero-Rosenfeld ME, Wang G, Schwartz I, Wormser GP (2005) Diagnosis of Lyme borreliosis. Clin Microbiol Rev 18:484-509
9. Centers for Disease Control and Prevention (1995) Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. Morb Mortal Wkly Rep 44:590-591
10. Marangoni A, Sambri V, Accardo S et al (2006) A decrease in the immunoglobulin G antibody response against the VlsE protein of Borrelia burgdorferi sensu lato correlates with the resolution of clinical signs in antibiotic-treated patients with early Lyme disease. Clin Vaccine Immunol 13:525-529